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Prions are infectious proteins, able to propagate and trans-
mit the infection from one individual to another without an
essential nucleic acid. In addition to this horizontal trans-
mission, typical of the mammalian transmissible
spongiform encephalopathies (TSEs), prions of fungi also
transmit the infection vertically (to their offspring), and so
they are proteins acting as genes, just as nucleic acids can act
as enzymes (Table 1).
Most prions are amyloids - filamentous polymers high in
β-sheet structure, usually protease resistant and with
characteristic staining properties. Prion transmission occurs
when donor amyloid enters the recipient cell and the
equivalent recipient protein joins to the ends of the amyloid
filaments, which act as a structural template, so that the
recipient protein adopts (usually) the same conformation as
the donor amyloid. The known prion-forming proteins of
yeast and mammals are listed in Table 1.
A single prion protein sequence can form any of several
biologically distinct prion ‘strains’ or ‘variants’, differen-
tiated in mammals by incubation time, disease signs and
lesion distribution, or in yeast by prion stability, phenotype
intensity or sensitivity to elevated or depressed levels of
particular chaperones (reviewed in [1,2]). Different prion
variants have different amyloid structures, although the
exact structures are as yet unknown.
C Cr ro os ss si in ng g   t th he e   s sp pe ec ci ie es s   b ba ar rr ri ie er r
Prions that are fully infectious between individuals of the
same mammalian or yeast species may transmit poorly - or
not at all - between species, a phenomenon called the species
barrier. In spite of centuries of exposure, sheep scrapie is not
known to have been transmitted to humans, but bovine
spongiform encephalopathy (BSE) has (fortunately only
rarely) done so. The primary determinants of the species
barrier are the sequences of the potential prion proteins of
the two species. However, the prion variant is also an
important factor. For example, the Ure2 nitrogen regulation
proteins of various Saccharomyces species can become prions
(called [URE3]), and species barriers are seen among these
[URE3]s that are dependent on the prion variant. While one
variant of the [URE3] prion of species A may transmit with
100% efficiency to species B, another variant may transmit
with 0% efficiency between the same two species [3].
A Ab bs st tr ra ac ct t
Prion variants faithfully propagate across species barriers, but if the barrier is too high, new
variants (mutants) are selected, as shown in a recent BMC Biology report. Protein sequence
alteration can prevent accurate structural templating at filament ends producing prion
variants.
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sequence has a range of possible conformers. A narrow
overlap of conformers between donor and recipient pro-
duces a high species barrier, while a wide overlap implies a
low barrier. Thus, according to this model, a specific
conformer common to donor and recipient could overcome
what would otherwise be a high species barrier [4]. It is
likely that interactions with chaperones or other cellular
factors, known to differ depending on prion variant, will be
found to be at least part of some species barriers [5].
In yeast, de novo formation of prions can, though rarely, be
primed by other prions. All of the prion-forming proteins of
yeast have asparagine/glutamine-rich prion domains, and
this shared structure is thought to enable prions of one of
the proteins to prime filament formation by others [6].
In fact, de novo generation of the [PSI+] prion of Saccharo-
myces cerevisiae is almost undetectable in a strain not
carrying one of the other prions. This cross-seeding
produces an array of prion variants, whereas passing a
species barrier usually produces a single, unchanged prion
variant in the recipient.
In both mammals and yeast, if a prion is successfully
transmitted to a new host, the variant produced in the
recipient is usually that of the donor. For example, when zoo
animals were infected with BSE, and those infections were
then introduced into mice, the same unique distribution of
brain lesions was seen as when mice were infected with BSE
directly from cows. Similarly, passing the [URE3] of one
species through Ure2p of a different species and then
returning it to the original Ure2p generally produces a
[URE3] prion 1with the same properties as the original [3].
In some cases, however, infection of a new species is so
inefficient - in other words, the species barrier is so high -
that disease only results if a ‘mutant’ prion is selected that
can replicate readily in the new host (Figure 1a). For
example, mouse scrapie strain 139A only produces disease in
hamsters after an extended incubation period (see, for
example [7]). Serial passage of the infection in hamsters then
eventually produced a shorter stable incubation period.
However, on passage from hamsters back into mice and after
the initial species barrier had subsided by a few passages, the
agent had a dramatically longer incubation period than the
original mouse scrapie and gave a different brain-lesion
profile. The conclusion from this classic experiment was that
a ‘mutant’ scrapie strain had been selected [7].
P Pr ri io on n   c cr ro os ss s- -s se ee ed di in ng g
An apparently analogous phenomenon has recently
been reported in BMC Biology by Vishveshwara and
Liebman using chimeric yeast prions [8]. The [PSI+]
prion of S. cerevisiae is based on an amyloid form of the
protein Sup35p, which normally functions as a translation
termination factor (Table 1). Sup35p has a glutamine
(Q)/asparagine (N)-rich amino-terminal prion domain (N)
- the domain responsible for amyloid formation - a charged
middle domain (M), and a carboxy-terminal domain (C),
which is responsible for Sup35p’s normal function of
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Organism Prion Protein Normal function Prion manifestation
Mammals TSEs PrP Not known Transmissible spongiform encephalopathy
Saccharomyces cerevisiae [URE3] Ure2 Nitrogen catabolite repression Derepression of nitrogen catabolism enzymes and 
transporters
[PSI+] Sup35 Translation termination Read-through of stop codons
[PIN+] Rnq1 Not known Rare seeding of [PSI+], other prions
[SWI+] Swi1 Chromatin remodeling Poor growth on glycerol, raffinose, galactose
[MCA] Mca1 Metacaspase (suspected  Unknown
function in apoptosis) 
[OCT+] Cyc8 Repression of CYC7 and  Derepression of transcription
other genes
[MOT3+] Mot3 Transcription factor Cell-wall changes
Podospora anserina [Het-s] HET-s Heterokaryon incompatibility;  Heterokaryon incompatibility; meiotic drive (as a 
meiotic drive (as a prion) prion)translation termination. A chimeric protein made by
fusing the similarly Q/N-rich N domain and the M
domain of Sup35 protein of the yeast Pichia methanolica to
the S. cerevisiae C domain (NMPM-CSC) will act as a prion,
called [CHI+
PM], when expressed in S. cerevisiae [9].
However, the considerable sequence difference between the
P. methanolica and S. cerevisiae Sup35 N domains results in a
species barrier between the two N domains, so that prion
transmission is rare.
Moreover, the rare prion transmission from [PSI+] to
[CHI+
PM] results in at least two different prion variants of the
chimera (Figure 1b) [8]. This indicates that the S. cerevisiae
Sup35N amyloid was not able to accurately template the
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Prion variant generation by cross-seeding could overcome species barriers to prion transmission. ( (a a) ) An altered form (a ‘mutant’) of mouse scrapie
strain 139A is selected by the high species barrier encountered when it is transferred to hamsters (modified from [7]). ( (b b) ) The species barrier
between the S. cerevisiae Sup 35 prion [PSI+] and a chimeric protein with a P. methanolica Sup35 prion domain results in the rare generation of
either of two [CHI+
PM] prion variants of the latter on exposure to [PSI+] [8]. ( (c c) ) Schematic diagram showing partial templating by species A amyloid
filament of species B protein. Species B protein sequence is incompatible with all of species A filament structure, and so assumes an altered self-
propagating form - a prion variant.
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The production of two [CHI+
PM] prion variants after
exposure of P. methanolica (Pm) Sup35 chimeric
protein to S. cerevisiae (Sc) [PSI+] could be due to
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conversionchimera, although its presence certainly induced prion
formation by the chimeric protein. In this case, it was
probably prion generation that was induced by [PSI+],
rather than transmission, although it remains possible that
one of the [CHI+
PM] variants corresponds to the original
[PSI+] variant.
The similarity between the scrapie ‘mutation’ phenomenon
and the yeast stimulated prion generation is striking. In
each case, sequence differences largely blocked duplication
of the donor prion conformation, resulting in only partial
templating and generation of altered prion variants. This
also is presumed to be the basis of the prion priming
phenomenon described above.
W Wh ha at t   i is s   t th he e   s st tr ru uc ct tu ur ra al l   b ba as si is s   o of f   v va ar ri ia an nt t   p ph he en no om me en na a? ?
The structure of infectious PrP is not yet known, but
infectious amyloids of the prion domains of Ure2p, Sup35p
and Rnq1p each have an in-register parallel β-sheet structure
(see, for example, [10]). Thus, each residue of the last mono-
mer to join the filament contacts the same residue of the
preceding monomer (Figure 1c). The register is maintained
by hydrogen bonds between Gln or Asn (the so-called β-
zipper) and possibly between Ser and Thr residues. A line of
hydrophobic residues down the fiber will likewise have
positive interactions, helping to keep the β-sheet in register.
The location of turns, the contacts between β-sheets and the
extent of β-sheet are thus transmitted to the newly joined
monomer. Combined with chain breakage to make new
seeds, this templating action can explain the heritability of
prion strains/variants [11]. A weakly homologous or non-
homologous (but still Q/N rich) monomer might interact
with part of the monomer on the end of the filament, so that
only part of its conformation was fixed. The remainder may
form by some stochastic interaction with another monomer
identical to itself (shown schematically in Figure 1c). This
could explain yeast prion cross-seeding and the ‘mutation’
phenomena using the known structural information.
A A   p pr ri io on n   w wi it th ho ou ut t   v va ar ri ia an nt ts s   i is s   e ev vo ol lv ve ed d   t to o   b be e   a a   p pr ri io on n: :
[ [H He et t- -s s] ]
Unlike the mammalian TSEs and the yeast prions [URE3]
and [PSI+], which are all diseases, the [Het-s] prion of the
filamentous fungus Podospora anserina is evolved to be a
prion [12]. It appears to function for the host in hetero-
karyon incompatibility, and to be the basis of a striking
meiotic drive phenomenon [13]. Which is the phenomenon
and which is the ‘epiphenomenon’ is not yet clear, but in
either case, the HET-s protein is evolved to be a prion. Only
a single prion variant of [Het-s] has been described, as
would be expected for a protein evolved to be a prion.
The infectivity and heritability of yeast prions and the ease
of yeast manipulation as exemplified by the work of
Vishveshwara and Liebman [8] make possible detailed
studies of different amyloid forms, their generation and
interaction with each other and with other cellular compo-
nents, that would be impossible in the non-infectious
amyloid diseases of mammals. Nonetheless, the findings
with the prions are applicable to the non-infectious amyloid
diseases that pose a burgeoning problem for our aging
populations. Both the cross-seeding phenomenon, as
suggested by the coincident occurrence of amyloids of Aβ
peptide, tau, α-synuclein and others in the human amy-
loidoses, and the variant phenomenon, as in the different
self-propagating amyloid forms of Aβ [14], are apparently
present in non-infectious amyloidoses.
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